X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs MYLAN (US) - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   MYLAN
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
MYLAN
Dec-14
DR. REDDYS LAB/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3,39760-   
Low Rs2,56042-   
Sales per share (Unadj.) Rs856.520.4-  
Earnings per share (Unadj.) Rs78.02.5-  
Cash flow per share (Unadj.) Rs139.94.0-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs739.810.1-  
Shares outstanding (eoy) m165.74378.37-   
Bonus/Rights/Conversions BBOI-  
Price / Sales ratio x3.52.5 139.7%   
Avg P/E ratio x38.220.7 184.8%  
P/CF ratio (eoy) x21.312.8 165.8%  
Price / Book Value ratio x4.05.0 80.4%  
Dividend payout %25.70-   
Avg Mkt Cap Rs m493,63219,221 2,568.2%   
No. of employees `00022.725.0 90.7%   
Total wages/salary Rs m31,0680-   
Avg. sales/employee Rs Th6,259.0308.8 2,026.9%   
Avg. wages/employee Rs Th1,369.80-   
Avg. net profit/employee Rs Th569.737.2 1,531.4%   
INCOME DATA
Net Sales Rs m141,9617,720 1,838.9%  
Other income Rs m1,715-45 -3,811.1%   
Total revenues Rs m143,6767,675 1,872.0%   
Gross profit Rs m24,7221,920 1,287.6%  
Depreciation Rs m10,266567 1,810.6%   
Interest Rs m634333 190.4%   
Profit before tax Rs m15,537975 1,593.5%   
Minority Interest Rs m0-4 0.0%   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,96541 7,231.7%   
Profit after tax Rs m12,921930 1,389.4%  
Gross profit margin %17.424.9 70.0%  
Effective tax rate %19.14.2 453.8%   
Net profit margin %9.112.0 75.6%  
BALANCE SHEET DATA
Current assets Rs m96,8376,787 1,426.8%   
Current liabilities Rs m84,1995,306 1,586.9%   
Net working cap to sales %8.919.2 46.4%  
Current ratio x1.21.3 89.9%  
Inventory Days Days7378 94.0%  
Debtors Days Days98107 91.0%  
Net fixed assets Rs m102,5521,786 5,742.0%   
Share capital Rs m829273 303.7%   
"Free" reserves Rs m121,7920-   
Net worth Rs m122,6213,838 3,195.3%   
Long term debt Rs m5,4495,733 95.0%   
Total assets Rs m218,16515,458 1,411.4%  
Interest coverage x25.53.9 649.4%   
Debt to equity ratio x01.5 3.0%  
Sales to assets ratio x0.70.5 130.3%   
Return on assets %6.28.2 76.0%  
Return on equity %10.524.2 43.5%  
Return on capital %12.913.6 94.7%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Net fx Rs m55,3150-   
CASH FLOW
From Operations Rs m21,4441,015 2,113.1%  
From Investments Rs m-18,404-800 2,299.6%  
From Financial Activity Rs m-3,692-267 1,380.7%  
Net Cashflow Rs m-1,144-53 2,162.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 1 Rs / USD

Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: UNICHEM LAB  PFIZER  JUBILANT LIFE SCIENCES  STERLING BIOTECH  AJANTA PHARMA  



Today's Market

Sensex Remains Positive; PSU & Power Stocks in Demand(01:30 pm)

After opening the day on a positive note, the Indian share markets have continued the momentum and are presently trading above the dotted line ahead of October F&O expiry and Infosys results.

Related Views On News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Rs 71 Trillion Business Could Make or Break (Your) Wealth in the Next Decade(The 5 Minute Wrapup)

Oct 17, 2017

How to profit from behavioral biases afflicting the industry.

Electric Vehicles: The Final Piece of the Puzzle(Smart Contrarian)

Oct 16, 2017

Just as there would be gainers from an electric vehicles boom, who possibly could be the biggest losers.

The Delusional Optimism of India's Real Estate Companies(Vivek Kaul's Diary)

Oct 16, 2017

This is a sector which hasn't gone anywhere in nearly six years, but those who run it continue to remain optimistic.

How Many Shares Should One Buy?(Daily Profit Hunter)

Oct 18, 2017

How much to buy is the biggest challenge after deciding what to buy. Here's your solution.

Companies Are Wary of Borrowing(Chart Of The Day)

Oct 17, 2017

How to profit from behavioral biases afflicting the industry.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2018
Get our special report, Multibagger Stocks Guide (2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 24, 2017 02:43 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS